GlassScriptPhysician profile
Najdat Bazarbashi
NPI 1427519016
$3,327.37
in general payments reported to CMS, 2019-2025
12 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $881 · 2024: $1,368 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,923 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,923.38 |
| Education | $403.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $707.93 | 2024-2025 | Onyx Frontier, Resolute Onyx, Symplicity G3 |
| Amgen INC. | $549.18 | 2023-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $496.94 | 2023-2025 | Lifevest |
| Abbott Laboratories | $494.91 | 2024-2025 | Triclip, Optis, Gallant |
| Boston Scientific Corporation | $356.28 | 2023-2024 | Avvigo Guidance System |
| Cvrx, INC. | $177.57 | 2025 | Barostim Neo System |
| Shockwave Medical, INC | $170.50 | 2025 | |
| Erbe USA INC | $140.17 | 2023 | Erbe Vio3 |
| Teleflex LLC | $126.72 | 2024 | Manta |
| W. L. Gore & Associates, INC. | $44.69 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Zoll Circulation INC | $32.00 | 2025 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Kestra Medical Technology Services, INC. | $30.48 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Najdat Bazarbashi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.